Experience with neoadjuvant chemotherapy in patients with breast cancer

Khawaja Farhan Zahid, Muhammad Kamran Siddique, Neelam Siddiqui, Narjis Muzaffar, Muhammad Asim, Muhammad Azfar

Research output: Contribution to journalArticle

Abstract

Objective: To determine the response rates to neoadjuvant chemotherapy in patients with breast cancer. Methods: Medical records of 161 women with breast cancer, registered at Shaukat Khanum Memorial Cancer Hospital between July 2006 and March 2008 were retrospectively reviewed. Patients were stratified into two groups based on the type of chemotherapy received; Group A (Anthracycline based regimens), Group B (Anthracycline and Taxane based regimens). Response rate was noted. Results: Clinical complete response rates by clinical examination were significantly higher in Group B as compared to Group A in both primary disease in breast and axillary nodes (39% vs. 20.3%, p = 0.01; 72.7% vs. 30.7%, p = 0.01, respectively). There was no difference in response rates by imaging between groups A and B in breast and axillary lymph nodes (12.5% vs. 17%, p = 0.4; 66.6% vs. 70.4%, p = 0.4, respectively). There was no difference in pCR rates between Group A and B (9.1% vs. 14.2%, p = 0.35). However, multivariate analysis showed significant increase in pCR rates by addition of taxanes (p = 0.028), in patients with poorly differentiated tumours (p = 0.028) and in those with axillary node negative disease by palpation (p = 0.016). There was no statistically significant difference in breast conservation rates between group A and B (25.4% vs. 36.7%, p = 0.1). Conclusion: Addition of taxanes to anthracycline based regimens improved the pathological complete response in our patients with breast cancer.

Original languageEnglish
Pages (from-to)284-287
Number of pages4
JournalJournal of the Pakistan Medical Association
Volume60
Issue number4
Publication statusPublished - Apr 2010

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Experience with neoadjuvant chemotherapy in patients with breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Zahid, K. F., Siddique, M. K., Siddiqui, N., Muzaffar, N., Asim, M., & Azfar, M. (2010). Experience with neoadjuvant chemotherapy in patients with breast cancer. Journal of the Pakistan Medical Association, 60(4), 284-287.